PolmoniAMO_INGL

31 PolmoniAMO 42. Lung cancer screening: the cost of inaction. LLA. July 2021. 43. Veronesi G, et al. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy. Lung Cancer 2020; 143:73-79. 44. Taksler GB, et al. Implications of false-positive results for future cancer screenings. Cancer 2018;124(11):2390-2398. 45. Paone S, et al. - Agenas - Report Adaptation - Screening per il tumore del polmone [Screening for lung cancer], July 2014. Available from: https://www.salute.gov.it/imgs/C_17_ReportDispositivi_17_0_documentoITA.pdf. Last accessed 12 February 2022. 46. Oudkerk M, et al. European position statement on lung cancer screening. Lancet Oncol 2017;18(12):e754-e766. 47. Un piano di lotta contro il cancro per l’Europa. [A cancer plan for Europe.] Available from: https://ec.europa.eu/info/ strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union/cancer-plan-europe_it. Last accessed 12 May 2022 48. https://ec.europa.eu/info/research-and-innovation/strategy/support-policy-making/scientific-support-eupolicies/ group-chief-scientific-advisors/cancer-screening_en. 49. Detterbeck FC, et al. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3(7):781-92. 50. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://apps.who.int/iris/bit- stream/handle/10665/330829/9789289054782-eng.pdf. Last accessed 12 February 2022. 51. Linee Guida AIOMNeoplasie del Polmone. [AIOMGuidelines on Lung Neoplasms.] Edition 2021. Available from: https:// snlg.iss.it/wpcontent/uploads/2021/11/LG-149_Polmone_agg2021.pdf. Last accessed 11 May 2022. 52. Kota KJ, et al. Lung Cancer Screening Knowledge and Perceived Barriers Among US Physicians. JTO Clinical and Re- search Reports, 2022. Available from: https://www.jtocrr.org/article/S2666-3643( 22)00055-8/fulltext. Last accessed 11 May 2022. 53. Katki HA, et al. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA 2016;315(21):2300-311. 54. Cheung LC, et al. Life-gained versus risk-based selection of smokers for lung cancer screening. Ann Intern Med 2019; doi:107326/M19.1263 55. Lebrett MB, et al. Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme. Thorax 2020;75:661-668. 56. Veronesi G, et al. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. Cancers 2020;12:1672. 57. https://www.epicentro.iss.it/passi/dati/ScreeningMammografico 58. Quaife, S.L., Vrinten, C., Ruparel, M. et al. Smokers’ interest in a lung cancer screening programme: a national survey in England. BMC Cancer 18, 497 (2018). https://doi.org/10.1186/s12885-018-4430-6 59. Proposta di riparto dei primi 8 miliardi dei fondi della missione 6 Salute del Piano nazionale di ripresa e resilienza PNRR. [Proposed allocation of the first 8 billion of the Mission 6 Health funds of the National Recovery and Resilience Plan (PNRR).] Available from: https://www.quotidianosanita.it/allegati/allegato2395614.pdf. Last accessed 10 February 2022. 60. Attuazione delle Misure del PNRR. [Implementation of PNRR Measures.] Missione 6 salute. [Mission 6 health.] Available from: https://www.quotidianosanita.it/allegati/allegato701286.pdf. Last accessed 10 February 2022. 61. Mathew CJ, et al. Artificial Intelligence and its future potential in lung cancer screening. EXCLI J 2020;19:1552-62.